Ritwik Maity

Mr. Ritwik Maity

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
RMRitwik Maity
Ritwik Maity
MCManosree Chatterjee
Manosree Chatterjee
ABAnmol Banerjee
Anmol Banerjee
ADAmlan Das
Amlan Das
RMRaghwendra Mishra
Raghwendra Mishra
NCNripen Chanda
Nripen Chanda

13 October 2020 in Materials Advances
Verified
Journal Article
Open access
PDF file
MCManosree Chatterjee
Manosree Chatterjee
RMRitwik Maity
Ritwik Maity
SDSouvik Das
Souvik Das
NMNibedita Mahata
Nibedita Mahata
BBBiswarup Basu
Biswarup Basu
NCNripen Chanda
Nripen Chanda
A novel approach used to synthesize antimetabolite-conjugated and intense blue fluorescence-emitting smart polymeric nanoparticles is reported for the efficient delivery of anticancer drugs and self-monitoring their effect in drug-resistant metastatic breast cancer cells.

Verified
Journal Article
Open access
PDF file
SSSandra Salillas
Sandra Salillas
Juan José José Galano FrutosJuan José José Galano Frutos
Juan José José Galano Frutos
AMALEJANDRO JOSÉ MAHÍA MOROS
ALEJANDRO JOSÉ MAHÍA MOROS
RMRitwik Maity
Ritwik Maity
MCMaría Conde-Giménez
María Conde-Giménez
Javier SanchoJavier Sancho
Javier Sancho
Antimicrobial resistant (AMR) bacteria constitute a global health concern. Helicobacter pylori is a Gram-negative bacterium that infects about half of the human population and is a major cause of peptic ulcer disease and gastric cancer. Increasing resistance to triple and quadruple H. pylori eradication therapies poses great challenges and urges the development of novel, ideally narrow spectrum, antimicrobials targeting H. pylori. Here, we describe the antimicrobial spectrum of a family of nitrobenzoxadiazol-based antimicrobials initially discovered as inhibitors of flavodoxin: an essential H. pylori protein. Two groups of inhibitors are described. One group is formed by narrow-spectrum compounds, highly specific for H. pylori, but ineffective against enterohepatic Helicobacter species and other Gram-negative or Gram-positive bacteria. The second group includes extended-spectrum antimicrobials additionally targeting Gram-positive bacteria, the Gram-negative Campylobacter jejuni, and most Helicobacter species, but not affecting other Gram-negative pathogens. To identify the binding site of the inhibitors in the flavodoxin structure, several H. pylori-flavodoxin variants have been engineered and tested using isothermal titration calorimetry. An initial study of the inhibitors capacity to generate resistances and of their synergism with antimicrobials commonly used in H. pylori eradication therapies is described. The narrow-spectrum inhibitors, which are expected to affect the microbiota less dramatically than current antimicrobial drugs, offer an opportunity to develop new and specific H. pylori eradication combinations to deal with AMR in H. pylori. On the other hand, the extended-spectrum inhibitors constitute a new family of promising antimicrobials, with a potential use against AMR Gram-positive bacterial pathogens.

8 September 2020 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
SSSelvendran Suresh
Selvendran Suresh
SDSouvik Das
Souvik Das
KWKamaran Waidha
Kamaran Waidha
RMRitwik Maity
Ritwik Maity
BBBiswarup Basu
Biswarup Basu
SRSaravanakumar Rajendran
Saravanakumar Rajendran

27 September 2024 in eLife
Verified
Journal Article
Open access
RMRitwik Maity
Ritwik Maity
XZXuepei Zhang
Xuepei Zhang
FLFrancesca Romana Liberati
Francesca Romana Liberati
CRChiara Scribani Rossi
Chiara Scribani Rossi
FCFrancesca Cutruzzolá
Francesca Cutruzzolá
Javier SanchoJavier Sancho
Javier Sancho
Antimicrobial resistance is responsible for an alarming number of deaths, estimated at 5 million per year. To combat priority pathogens, like Helicobacter pylori, the development of novel therapies is of utmost importance. Understanding the molecular alterations induced by medications is critical for the design of multi-targeting treatments capable of eradicating the infection and mitigating its pathogenicity. However, the application of bulk omics approaches for unraveling drug molecular mechanisms of action is limited by their inability to discriminate between target-specific modifications and off-target effects. This study introduces a multi-omics method to overcome the existing limitation. For the first time, the Proteome Integral Solubility Alteration (PISA) assay is utilized in bacteria in the PISA-Express format to link proteome solubility with different and potentially immediate responses to drug treatment, enabling us the resolution to understand target-specific modifications and off-target effects. This study introduces a comprehensive method for understanding drug mechanisms and optimizing the development of multi-targeting antimicrobial therapies.